{"disease":{"id":"resected-pancreatic-adenocarcinoma","name":"resected pancreatic adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07252232","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT03885284","title":"Study of Proton Therapy in Adjuvant Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Georgetown University","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}